Supplier News

Freudenberg Expands Biopharm Product Portfolio with Addition of Custom Single-Use Assemblies

August 06, 2024

Freudenberg Medical has introduced custom single-use assemblies for silicone extrusion and molding for biopharma applications.

Scorpius Holdings Prepares for Mammalian CGMP Manufacturing Campaign Launch in Texas Facility

July 27, 2024

Scorpius Holdings is set to launch its first CGMP manufacturing campaign at its San Antonio, Texas, facility for mammalian cell culture in the 2024 third quarter.

Two SpotSee Products Receive AABB Standards Accreditation

July 26, 2024

The HemoTemp II Blood Bag Temperature Indicator, which is an FDA-approved medical device, and the HemoTemp II Activator both were given the “Standards-Compliant” seal.

Univercells and University of Pennsylvania Expand Agreement for Gene Therapy Program

July 25, 2024

Univercells and the University of Pennsylvania are expanding their collaboration to evaluate certain bioreactors with the aim to scale up gene therapy manufacturing.

Agilent Expands Biopharma Offerings with BIOVECTRA Acquisition

July 23, 2024

The addition of BIOVECTRA’s biologics capabilities to accelerate drug development and manufacturing will allow Agilent to expand its end-to-end offerings for biopharma services.

Kadimastem and Pluri Enter Cell Therapy Manufacturing Deal

July 20, 2024

PluriCDMO, Pluri's newly launched CDMO division, has been selected by Kadimastem to manufacture two novel cell therapy product candidates.

Thermo Fisher Scientific Expands Proteomics Services with Olink Acquisition

July 13, 2024

Thermo Fisher will add Olink to its Life Sciences Solutions business.

Cell-Free Protein Synthesis Technology to be Made More Accessible Through LenioBio and Labscoop Partnership

July 04, 2024

LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.

Aurigene to Provide Cell Therapy Discovery Services to Edity to Support Clinical Development

July 02, 2024

This collaboration aims to support and accelerate clinical development of advanced and novel technologies.

Lantheus Acquires Rights to Life Molecular’s RM2 Targeting GRPR for Prostate and Breast Cancers

June 27, 2024

GRPR, or gastrin-releasing peptide receptor, is part of the bombesin G protein-coupled receptor family and has been found to be overexpressed in multiple cancers.